TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03278288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WellWe-Intervention group
Description: Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
Study: NCT05875155

Intervention type: DIAGNOSTIC_TEST
Intervention: Infectious Disease Labwork
Description: Infectious disease labs will be drawn and resulted.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fertility-Based Labwork
Description: Other labwork to understand fertility may be drawn.
Study: NCT02150824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 medium dose matching placebo once daily
Study: NCT03610997

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photorefractive keratectomy
Study: NCT03211637

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Wounds Protocol
Description: Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Wounds Protocol
Description: Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
Study: NCT01450072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Venography followed by therapeutic balloon angioplasty
Description: Venography followed by therapeutic balloon angioplasty

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control arm
Description: Venography and sham angioplasty
Study: NCT02150824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 high dose matching placebo once daily add on to background metformin
Study: NCT02512042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test-Brinzolamide 1% Ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference-Brinzolamide 1% Ophthalmic suspension
Study: NCT01964261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Prosthetic System 2 (NPS2)
Description: The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
Study: NCT04073420

Intervention type: DEVICE
Intervention: Surgical Heart Valve Repair Products
Description: Surgical heart valve repair products.

Intervention type: DEVICE
Intervention: Surgical Heart Valve Replacement Products
Description: Surgical heart valve replacement products.
Study: NCT03158246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Zoledronic Acid
Description: Generic Zoledronic Acid (Yigu®) 5mg/100ml injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original Zoledronic Acid
Description: Original Zoledronic Acid (Aclasta®) 5mg/100ml injection

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: 600mg/d calcium for oral daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: 600mg/d calcium for oral daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 925IU/d vitamin D for oral daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 925IU/d vitamin D for oral daily
Study: NCT01644331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
Study: NCT02346279

Intervention type: OTHER
Intervention: Questionnaires, EDSS, physical test
Description: 6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
Study: NCT01161966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide capsules 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: Zonegran Capsules 100 mg of EISAI INC
Study: NCT02221726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-35684-AAA-023: Size 1; small patch
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-35684-AAA-023: Size 2; large patch
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
Study: NCT02779231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bi-directional texting
Study: NCT02354573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivabradine
Description: All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
Study: NCT01784484

Intervention type: OTHER
Intervention: No intervention
Study: NCT02085980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
Study: NCT04046744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus block with a long-acting local anesthetic
Description: axillary block with 15-30 ml Ropivacaine 0,5%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic
Description: axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: axillary block with 15-30 ml Ropivacaine 0,5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: axillary block with 15-30 ml Lidocaine 1,5%
Study: NCT02138500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
Study: NCT04847856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.
Description: The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
Study: NCT04279405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 80mg tablet administered orally once daily
Study: NCT00045968

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dendritic cell immunotherapy
Description: Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic cell immunotherapy
Description: Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
Study: NCT03068611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Web-based Smoking Cessation
Description: A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-focused Web-Based Smoking Cessation
Description: A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
Study: NCT05038670

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
Study: NCT03562910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HelpSteps application
Description: Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
Study: NCT03031132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HP-Beverage Breakfast
Description: Participants will consume high protein beverage (shake) breakfast meals each morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HP-Solid Breakfast
Description: Participants will consume high protein solid (traditional food items) breakfast meals each morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast Skipping
Description: Participants will skip breakfast each morning.
Study: NCT01851460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cool-tip RF Ablation System
Description: RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of \>75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
Study: NCT03240354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline cuff
Description: Cuff of endotracheal tube inflated with saline rather than air (control)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Cuff of endotracheal tube inflated with air
Study: NCT02105883

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of identification badge during scenarios
Study: NCT01694264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
Study: NCT04650022

Intervention type: DEVICE
Intervention: Mechanical thrombectomy
Description: Stent retriever for treatment of cerebral arterial occlusions
Study: NCT02150824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 high dose once daily add on to background metformin
Study: NCT01655056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study: NCT00619736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789
Study: NCT02150824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 low dose matching placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 medium dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 low dose once daily
Study: NCT01655056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT03236883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPBSC
Description: immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.

Intervention type: OTHER
Group type: OTHER
Intervention: GPBSC
Description: immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.
Study: NCT00797303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
Study: NCT00321932

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Given orally
Study: NCT04428320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor injection
Description: Injection of 10 cc of bupivacaine
Study: NCT03462199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actazin (green kiwi powder) High Dose
Description: Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actazin (green kiwi powder) Low Dose
Description: Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula (Actazin green kiwi powder + PreticX prebiotic)
Description: Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Livaux (gold kiwi powder) High Dose
Description: Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Livaux (gold kiwi powder) Low Dose
Description: Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Description: Participants will consume 4 capsules containing no active ingredients daily for 28-days
Study: NCT01194258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study: NCT00321932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
Study: NCT05787041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat diet group（AD16 20mg）
Description: AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasted group（AD16 20mg）
Description: Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
Study: NCT04431063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Stump Suturing
Description: in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
Study: NCT01194258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study: NCT00619736

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01194258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Study: NCT00197236

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: 2 intramuscular injections, 6 months apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: 2 intramuscular injections, 6 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: 2 intramuscular injections, 6 months apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™
Description: 1 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™
Description: 1 intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB™
Description: 1 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ActHIB™
Description: 1 intramuscular injection
Study: NCT01846169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food deliveries
Description: Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
Study: NCT00362206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate and Simvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate and Simvastatin 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg
Study: NCT00383188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsule, once daily (QD) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
Study: NCT02150824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 high dose once daily